Association of clinical covariates and survival with the DELFI score

DM Dimitrios Mathios
JJ Jakob Sidenius Johansen
SC Stephen Cristiano
JM Jamie E. Medina
JP Jillian Phallen
KL Klaus R. Larsen
DB Daniel C. Bruhm
NN Noushin Niknafs
LF Leonardo Ferreira
VA Vilmos Adleff
JC Jia Yuee Chiao
AL Alessandro Leal
MN Michael Noe
JW James R. White
AA Adith S. Arun
CH Carolyn Hruban
AA Akshaya V. Annapragada
SJ Sarah Østrup Jensen
Mai-Britt Worm Ørntoft
AM Anders Husted Madsen
BC Beatriz Carvalho
MW Meike de Wit
JC Jacob Carey
ND Nicholas C. Dracopoli
TM Tara Maddala
KF Kenneth C. Fang
AH Anne-Renee Hartman
PF Patrick M. Forde
VA Valsamo Anagnostou
JB Julie R. Brahmer
RF Remond J. A. Fijneman
HN Hans Jørgen Nielsen
GM Gerrit A. Meijer
CA Claus Lindbjerg Andersen
AM Anders Mellemgaard
SB Stig E. Bojesen
RS Robert B. Scharpf
VV Victor E. Velculescu
request Request a Protocol
ask Ask a question
Favorite

We performed univariate analyses comparing the distribution of the DELFI score to baseline clinical and laboratory covariates age, smoking, and serum inflammatory markers using a Wilcoxon rank sum test. In addition, we evaluated the relationship of the DELFI score and cancer risk with and without baseline covariates age, smoking, and sex using logistic regression.

To assess whether the DELFI score was associated with prognosis, we categorized high-risk lung cancer patients according to whether they were more likely to have cancer than not (DELFI score > 0.5). To assess whether this categorization was associated with survival among lung cancer patients in a univariate analysis, we used a log rank test to compare survival curves (Supplementary Table 6). While we did not optimize the 0.5 cutoff, we verified that inference from the log rank test was robust to other possible choices that would achieve higher or lower specificities, including a range of DELFI score cutoffs of 0.3–0.95. In addition to the univariate analysis, we evaluated whether the DELFI score was independently associated with cancer-specific survival in a multivariable Cox proportional hazards model that included age, histological subtypes of primary lung cancer, clinical staging, as well as treatment modality.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A